Consumers Find LivRing® Effectively Addresses Needs for Vaginal Dryness Relief
'I was particularly encouraged by the positive correlation between the reported increases in excitement and desire for intimacy connected to the use of the LivRing.'— Dr. Sheryl A. Kingsberg
SALT LAKE CITY, UT, UNITED STATES, May 21, 2025 / EINPresswire.com / -- J3 Bioscience, a commercialization-stage women's health company, today announced consumer feedback results from LivRing® users that underscore the product's robust performance in providing long-lasting moisturization and lubrication. The findings demonstrate the effectiveness of LivRing in addressing symptoms commonly associated with vaginal dryness - the second most common symptom of menopause - offering a meaningful new option to women seeking clinically tested, non-hormonal, and readily accessible solutions.
Summary of Feedback: In a recent consumer feedback review, participants evaluated their experience using a standardized 5-point Likert scale where a rating of (5) corresponded to 'Very Satisfied,' indicating a high level of satisfaction with positive statements regarding the attributes of LivRing, while a rating of (1) represented 'Very Unsatisfied' reflecting minimal or no perceived benefit.
The consumer feedback data revealed consistently high levels of satisfaction across all key areas of measurement including:
- Perception and First Impressions: Participants reported favorable initial responses, indicating that the product met or exceeded expectations in terms of appearance and physical dimensions.
- Daily Use and Comfort: When asked whether they could feel LivRing during daily use, participants gave LivRing an average score approaching 5, and 91% of participants either never or almost never noticed it.
- Confidence and Sexual Excitement: Participants reported that their confidence and excitement around sexual activity were positively impacted.
- Overall Satisfaction and Advocacy: The overall experience score, along with participants' intent to continue using LivRing, and the likelihood to recommend LivRing all scored very high.
J3 Bioscience Board member and Chief of Behavioral Medicine at University Hospitals Cleveland Medical Center, Dr. Sheryl A. Kingsberg added, 'I'm very encouraged by these data as they underpin some important benefits to women that are looking for a non-prescription product. Conditions like vaginal dryness can often have a negative impact on sexual arousal as well as a desire for intimacy. As a researcher in the field of sexual health and medicine, I was particularly encouraged by the positive correlation between the reported increases in excitement and desire for intimacy connected to the use of the LivRing.'
'These results validate our scientific approach to addressing unmet needs in women's health,' said John Fair, President and CEO of J3 Bioscience. 'LivRing is an FDA-cleared, fast-acting, long-lasting, hormone-free product designed to treat the symptoms commonly associated with vaginal dryness, and sets a new standard in the category. We are excited to offer a new treatment option to the millions of women seeking relief from this life-altering condition.'
LivRing was designed to offer relief for women experiencing vaginal dryness, which presents with intimacy-related issues, such as lack of lubrication and moisturization, as well as non-intimacy concerns, including persistent and uncomfortable itch or irritation. LivRing is the first and only FDA-cleared, over-the-counter vaginal ring designed to provide a continuous benefit of up to 7-days for each ring, which is the longest in the category.
About J3 Bioscience, Inc.:
J3 Bioscience, Inc. is a commercialization-stage, specialty women's health and wellness company headquartered in Salt Lake City, Utah. Focused on conditions that impact women throughout the course of their lives, J3 Bioscience develops innovative solutions that address long-overlooked needs in women's health. With a strong commitment to clinical integrity, user-centered design, and long-term impact, J3 Bioscience is advancing a new standard of care in women's health.
About LivRing:
LivRing®, is the first and only intravaginal ring that is FDA-cleared as a vaginal lubricant and vaginal moisturizer. LivRing is available without a prescription and represents a new and effective solution for women experiencing vaginal dryness. For more information, please visit www.Liv-Ring.com
Media Contact:
Madelyn De Los Santos
Putnam Insights LLC
[email protected]
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Lilly to acquire Verve in $1B bet on gene editing for heart disease
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Eli Lilly agreed to buy Verve Therapeutics for $1 billion, betting on the promise of one-and-done gene therapies to treat cardiovascular disease. The deal announced Tuesday offers Verve stockholders $10.50 a share, plus a contingent value right worth another $3 a share. The non-tradeable CVR would pay out if the company's experimental VERVE-102 treatment advances enough to dose a patient in a Phase 3 trial within 10 years of the transaction's closing. Verve CEO Sekar Kathiresan and other top stockholders have already agreed to tender shares that represent about 17.8% of Verve's outstanding stock and the gene editing company's board recommends that all investors agree to the tender offer, Lilly said. A second-step merger will follow if needed. The companies expect to complete the transaction in the third quarter. For Lilly, the acquisition offers greater control of a pipeline it's already invested in. The company inked a deal with Verve in 2023 to develop a product now known as VERVE-301 that's still in preclinical research. Later that year, Lilly bought other Verve opt-in rights from Beam Therapeutics that include the program for VERVE-102. 'The deal makes sense for Verve shareholders and makes sense given the exposure Lilly has to Verve's entire disclosed pipeline,' William Blair analyst Myles Minter wrote in a note to clients. Lilly is also stepping in at a time when Verve shares are undervalued, Minter said. Verve went public in 2021 with one of the largest initial offerings of the year in the biotech industry, raising almost $270 million by selling shares at $19 each. As an investment boom continued that year amid high hopes for gene therapies, Verve's shares soared above $70. But the company's lead product, VERVE-101, encountered safety concerns and Verve decided to scrap it in favor of a successor, VERVE-102, that used a different lipid nanoparticle for delivery of the treatment. That product has shown early promise. Even so, Verve shares closed at $6.27 yesterday, hurt by a general slump in investment in cell and gene therapy companies. 'Eli Lilly is getting a bargain here,' Minter wrote. Still, the 67% premium to the current share price is 'a win for Verve shareholders and the gene editing space more broadly, which has been under significant macro pressure in a difficult funding environment.' The CVR is likely to pay out, Minter said. The timeframe of 10 years shouldn't be an issue; dosing in a Phase 3 trial is more dependent on continued demonstration of safety in earlier-stage research, he wrote. The larger question for Lilly is whether patients and doctors will embrace genetic medicines for cardiovascular disease, when more traditional treatment options are readily available. Other companies have struggled in that situation. Verve counters that many patients drop off standard medications, putting themselves in danger of complications like a heart attack. The company's lead product is administered as an infusion, which also sets it apart from the complicated administration process that underlies high-profile gene editing treatments such as Vertex's Casgevy. Verve's medicine 'could shift the treatment paradigm for cardiovascular disease from chronic care to one-and-done treatment,' Ruth Gimeno, Lilly's group vice president for diabetes and metabolic research and development, said in the company's press release. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
35 minutes ago
- Associated Press
New CDC advisers will skip some expected topics and explore a target of antivaccine activists
U.S. Health Secretary Robert F. Kennedy Jr.'s new vaccine advisers meet next week, but their agenda suggests they'll skip some expected topics — including a vote on COVID-19 shots — while taking up a longtime target of anti-vaccine groups. The Advisory Committee on Immunization Practices makes recommendations on how to use the nation's vaccines, setting a schedule for children's vaccines as well as advice for adult shots. Last week, Kennedy abruptly dismissed the existing 17-member expert panel and handpicked eight replacements, including several anti-vaccine voices. The agenda for the new committee's first meeting, posted Wednesday, shows it will be shorter than expected. Discussion of COVID-19 shots will open the session, but the agenda lists no vote on that. Instead, the committee will vote on fall flu vaccinations, on RSV vaccinations for pregnant women and children and on the use of a preservative named thimerosal that's in a subset of flu shots. It's not clear who wrote the agenda. No committee chairperson has been named and the U.S. Department of Health and Human Services did not comment. Committee won't take up HPV or meningococcal vaccines Missing from the agenda are some heavily researched vaccine policy proposals the advisers were supposed to consider this month, including shots against HPV and meningococcal bacteria, said Dr. Susan Kressly, president of the American Academy of Pediatrics. Instead, the committee is talking about subjects 'which are settled science,' she said. 'Every American should be asking themselves how and why did we get here, where leaders are promoting their own agenda instead of protecting our people and our communities,' she said. She worried it's 'part of a purposeful agenda to insert dangerous and harmful and unnecessary fear regarding vaccines into the process.' The committee makes recommendations on how vaccines that have been approved by the Food and Drug Administration should be used. The recommendations traditionally go to the Centers for Disease Control and Prevention director. Historically, nearly all are accepted and then used by insurance companies in deciding what vaccines to cover. But the CDC has no director and the committee's recommendations have been going to Kennedy. Thimerosal is a longtime target of antivaccine activists Thimerosal was added to certain vaccines in the early 20th century to make them safer and more accessible by preventing bacterial contamination in multi-dose vials. It's a tiny amount, but because it's a form of mercury, it began raising questions in the 1990s. Kennedy — a leading voice in an antivaccine movement before he became President Donald Trump's health secretary — has long held there was a tie between thimerosal and autism, and also accused the government of hiding the danger. Study after study has found no evidence that thimerosal causes autism. But since 2001, all vaccines manufactured for the U.S. market and routinely recommended for children 6 years or younger have contained no thimerosal or only trace amounts, with the exception of inactivated influenza vaccine. Thimerosal now only appears in multidose flu shot vials, not the single-shot packaging of most of today's flu shots. Targeting thimerosal would likely force manufacturers to switch to single-dose vials, which would make the shots 'more expensive, less available and more feared,' said Paul Offit, a vaccine expert at Children's Hospital of Philadelphia. Doctors' groups have opposed Kennedy's vaccine moves Last week, 30 organizations called on insurers to continue paying for COVID-19 vaccines for pregnant women after Kennedy said the shots would no longer be routinely recommended for that group. Doctors' groups also opposed Kennedy's changes to the vaccine committee. The new members he picked include a scientist who researched mRNA vaccine technology and became a conservative darling for his criticisms of COVID-19 vaccines, a top critic of pandemic-era lockdowns and a leader of a group that has been widely considered to be a source of vaccine misinformation. The American Academy of Pediatrics has long put out its own immunization recommendations. In recent decades it has matched what the government recommended. But asked if they might soon diverge, depending on potential changes in the government's vaccination recommendations, Kressly said; 'Nothing's off the table.' 'We will do whatever is necessary to make sure that every child in every community gets the vaccines that they deserve to stay healthy and safe,' she said. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Yahoo
40 minutes ago
- Yahoo
Lindus Health Named Fierce CRO Award Winner in the Outstanding Patient Recruitment and Retention Category
BOSTON, June 18, 2025 /PRNewswire/ -- Lindus Health, the anti-CRO running radically faster, more reliable clinical trials, has been honored the winner in the 2025 Fierce CRO Awards' Outstanding Patient Recruitment and Retention category, which celebrate exceptional achievements and innovations by Contract Research Organizations (CROs). These awards spotlight CROs that exemplify innovation, performance, and leadership in advancing life sciences research and improving patient outcomes. Lindus Health earned this recognition for its innovative use of the Patient Identification Center (PIC) technique, which leverages advanced algorithms and customized search protocols based on real-world medical record data to reduce screen fail rates and accelerate recruitment with greater precision. This approach was instrumental in its collaboration with Myota on a pre-diabetes trial, which achieved a 54% screening conversion rate—five times the industry benchmark—and completed enrollment in just four months. Backed by deep expertise in healthcare data, clinical systems, and physician behavior, Lindus Health's unique PIC approach stands out not just for using EHR-driven participant searches, but for how it executes them. While many CROs rely on medical practices to run standard queries, Lindus builds its own highly customized, in-house searches. These go beyond basic inclusion and exclusion criteria, incorporating a nuanced understanding of how data is actually recorded and coded by general practitioners. For example, when a trial sought patients with "reduced sexual desire," Lindus optimized results by using "low libido"—a term more commonly coded by GPs—significantly improving the ability to identify eligible participants. "Receiving the Fierce CRO Award is a tremendous honor," said Meri Beckwith, co-founder of Lindus Health. "It reflects our mission to fix the broken clinical trial model so patients can access treatments faster. With innovative strategies like our PIC technique, smart study design, and proprietary AI, we're delivering faster, more precise, and cost-effective trials—even in complex cases. Our work isn't done though, and we're continuing to push the boundaries of what's possible in clinical research, making it more efficient, inclusive, and patient-centric every step of the way." This award comes on the heels of Lindus Health's Series B funding round of $55 million, which is fueling strategic hiring across clinical operations and product development, while expanding the capabilities of its proprietary AI-powered eClinical platform, Citrus™. The investment is enabling advancements in study design optimization, automated central monitoring, and real-time biostatistics. As the only major service provider with a fully in-house platform, Lindus integrates all core clinical research technologies—including CTMS, EDC, eDiary, visit scheduling, and more—into a seamless, unified ecosystem. In partnership with Oxford University, Lindus Health published a study on diverse perceptions of clinical trial participation, helping to inform more inclusive and patient-centered research. Additionally, Lindus is collaborating with CDISC, the organization that sets clinical data standards for the FDA, to develop standardized templates for clinical observations and is contributing to ARIA's Safeguarded AI program to improve trial design through safer, more reliable AI. The full Fierce CRO Awards report profiling all winners is available here. Lindus Health's award-winning capabilities can be found at About Lindus Health Lindus Health is an anti-CRO running radically faster, more reliable clinical trials for life science pioneers – bringing ground-breaking treatments to patients more quickly. This is achieved through a commercial model that aligns incentives (fixed-priced quotes per study, with milestone-based payments), a world-class clinical operations team with its unique software platform, and access to over 40 million Electronic Health Records. Clinical trials are the biggest bottleneck to advances in healthcare. Lindus Health removes this constraint through end-to-end execution of clinical studies driven by technology and forward-thinking approaches to clinical operations. To date, Lindus Health has delivered clinical trials across the US, UK, and Europe to tackle a range of conditions, including diabetes, asthma, acne, social anxiety, major depressive disorder, hypertension, chronic fatigue syndrome and insomnia. The company has raised over $80M from investors including Peter Thiel, Balderton, Creandum, Firstminute Capital, and Seedcamp. About Fierce BiotechFierce Biotech is the biotech industry's daily monitor, providing the latest news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 300,000 top biotech professionals rely on Fierce Biotech for an insider briefing on the day's top stories. Signup is free here. Press contact: Jodi PerkinsAmendola Communications for Lindus HealthJperkins@ Cell: 847.508.0877 View original content to download multimedia: SOURCE Lindus Health
